GW Pharmaceuticals PLC Result of AGM (1066T)

TIDMGWP

RNS Number : 1066T

GW Pharmaceuticals PLC

23 March 2016

GW Pharmaceuticals Announces Results of Annual General Meeting

Cambridge, UK, 23 March 2016: GW Pharmaceuticals plc (AIM: GWP, NASDAQ: GWPH or the "Company") hereby provides notification that, at the Annual General Meeting of the Company held earlier today, all the resolutions set out in the Notice of Meeting sent to shareholders were duly proposed and passed.

All resolutions were approved on a show of hands. Details of the proxy votes received in relation to each of the resolutions (which are more particularly described in the Notice of General Meeting) are as follows:

 
                              For(1, 2)              Against(1)             Withheld 
---------------------------  ---------------------  --------------------  ---------- 
 Ordinary resolutions 
------------------------------------------------------------------------  ---------- 
 Resolution 1 - To 
  receive, consider 
  and adopt the Directors' 
  and Auditors' Reports 
  and Statement of 
  Accounts for the 
  year ended 30 September 
  2016                        224,039,382   99.80%   450,875      0.20%     285,420 
---------------------------  ------------  -------  -----------  -------  ---------- 
 Resolution 2 - To 
  approve the Directors' 
  Remuneration Report         220,340,924   98.19%   4,051,711    1.81%     383,042 
---------------------------  ------------  -------  -----------  -------  ---------- 
 Resolution 3 - To 
  re-elect Adam George 
  as a Director               199,151,339   88.76%   25,229,611   11.24%    394,727 
---------------------------  ------------  -------  -----------  -------  ---------- 
 Resolution 4 - To 
  re-elect James Noble 
  as a Director               219,904,356   98.00%   4,491,570    2.00%     379,751 
---------------------------  ------------  -------  -----------  -------  ---------- 
 Resolution 5 - To 
  re-elect Christopher 
  Tovey as a Director         199,224,442   88.78%   25,176,764   11.22%    374,471 
---------------------------  ------------  -------  -----------  -------  ---------- 
 Resolution 6 - To 
  re-elect Julian 
  Gangolli as a Director      193,476,666   86.22%   30,921,912   13.78%    377,099 
---------------------------  ------------  -------  -----------  -------  ---------- 
 Resolution 7 - To 
  re-appoint Deloitte 
  LLP as Auditor              224,411,844   99.90%   222,865      0.10%     140,968 
---------------------------  ------------  -------  -----------  -------  ---------- 
 Resolution 8 - To 
  authorise the Directors 
  to determine the 
  Auditor's remuneration      224,066,168   99.79%   478,704      0.21%     227,680 
---------------------------  ------------  -------  -----------  -------  ---------- 
 Resolution 9 - To 
  authorize an increase 
  in the aggregate 
  annual limit on 
  the fees payable 
  to Directors to 
  GBP1,000,000                222,644,542   99.20%   1,794,438    0.80%     333,570 
---------------------------  ------------  -------  -----------  -------  ---------- 
 Special Resolutions (requires 75% majority) 
------------------------------------------------------------------------  ---------- 
 Resolution 10 - 
  That the Directors 
  be authorised to 
  disapply pre-emption 
  rights for cash 
  issues of up to 
  20% of the Company's 
  issued share capital        181,835,330   81.02%   42,586,722   18.98%    353,625 
---------------------------  ------------  -------  -----------  -------  ---------- 
 

(1) A vote withheld is not a vote in law and, is not counted in the calculation of the votes for or against a resolution. Therefore, the percentage of votes cast excludes withheld votes.

(2) Proxy forms which gave the Chairman or other officer of the Company discretion have been included in the "For" total.

On 23 March 2016, there were 262,717,686 GW Pharmaceuticals plc ordinary shares in issue. Shareholders are entitled to one vote per share held.

The full text of each resolution passed at the Annual General Meeting held earlier today, Wednesday 23 March 2016, is set out in the Notice of Annual General Meeting which is available for viewing on the Company's website at www.gwpharm.com.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R), which is approved for the treatment of spasticity due to multiple sclerosis in 28 countries outside the United States. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R) (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome and Lennox-Gastaut syndrome and which is also expected to enter Phase 3 clinical trials in the treatment of Tuberous Sclerosis Complex. GW has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, type 2 diabetes, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

For further information, please contact:

 
 GW Pharmaceuticals plc 
 Adam George, Company Secretary    [phone] 
 Peel Hunt LLP (UK NOMAD) 
 James Steel                       [phone] 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

RAGUORBRNVAOUAR

(END) Dow Jones Newswires

March 23, 2016 13:07 ET (17:07 GMT)